UnknownNot Applicable

Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS

50 participantsStarted 2021-01-01

Plain-language summary

1. assessment of the penefit of erythropoietin administration in decreasing the frequency of blood transfusion in adult low risk MDS 2. assessement of the clinical significance of the relationship between hyperfibrinogenemia and the prognosis of patients with low risk MDS 3. assessement of the association between serum ferritin levels and patient \_reported aspects and symptomes

Who can participate

Age range40 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * the participants are :adult low risk(IPSS score (2-3) myelodysplastic patients with median age (40-60) Exclusion Criteria: * patients with hiigh and intermediate risk MDS

What they're measuring

effect of erythropoietin on MDS prognosis

Timeframe: 1 year

Trial details

NCT IDNCT04573686

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-01-01

View on ClinicalTrials.gov More MDS trials